Chongcheng Xi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chongcheng Xi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Jie Zhang
Chongqing Health College, Chongqing, China
2 shared publicationsBeibei He
School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publication- Chuanbiao Wen
School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publication Hua Ye
School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
1 shared publicationHui-Ru Wang
Hubei University of Chinese Medicine, China
1 shared publication- Jin-Tao Liu
Beijing University of Chinese Medicine, China
1 shared publication
Latest Publications
- Open Access
- 31 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1659184
In-hospital mortality risk prediction models for patients with acute coronary syndrome: a systematic review and meta-analysis
Objective: To systematically evaluate in-hospital mortality risk prediction models for patients with acute coronary syndrome (ACS) and provide valuable insights and references for the construction, application, and optimization of these models. Methods: A comprehensive search was conducted in five databases, including CNKI, Wanfang, PubMed, Web of Science, and Embase, from inception to November 2024. Researchers screened the literature, extracted relevant data, and assessed the quality of the prediction models using the Prediction Model Risk of Bias Assessment Tool (PROBAST). Extracted data included study design, data sources, outcome definitions, sample size, predictive factors, model development, and performance. Results: A total of 18 studies involving 44 prediction models were included. The area under the receiver operating characteristic curve (AUC) or C-index of these models ranged from 0.79 to 0.96. Overall, the included prediction models demonstrated a high risk of bias, primarily due to issues such as unreported missing data, methodological flaws in model construction, and a lack of model performance evaluation. Conclusion: The construction of in-hospital mortality risk prediction models for patients with ACS is still in the developmental stage. Future development and validation of prediction models should adhere to the PROBAST and TRIPOD guidelines to establish models with strong predictive performance and high generalizability. Systematic Review Registration: PROSPERO CRD42024567755.
- 31 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1659184
Open AccessIn-hospital mortality risk prediction models for patients with acute coronary syndrome: a systematic review and meta-analysis
Objective: To systematically evaluate in-hospital mortality risk prediction models for patients with acute coronary syndrome (ACS) and provide valuable insights and references for the construction, application, and optimization of these models. Methods: A comprehensive search was conducted in five databases, including CNKI, Wanfang, PubMed, Web of Science, and Embase, from inception to November 2024. Researchers screened the literature, extracted relevant data, and assessed the quality of the prediction models using the Prediction Model Risk of Bias Assessment Tool (PROBAST). Extracted data included study design, data sources, outcome definitions, sample size, predictive factors, model development, and performance. Results: A total of 18 studies involving 44 prediction models were included. The area under the receiver operating characteristic curve (AUC) or C-index of these models ranged from 0.79 to 0.96. Overall, the included prediction models demonstrated a high risk of bias, primarily due to issues such as unreported missing data, methodological flaws in model construction, and a lack of model performance evaluation. Conclusion: The construction of in-hospital mortality risk prediction models for patients with ACS is still in the developmental stage. Future development and validation of prediction models should adhere to the PROBAST and TRIPOD guidelines to establish models with strong predictive performance and high generalizability. Systematic Review Registration: PROSPERO CRD42024567755.
- Open Access
- 15 January 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1522619
Risk prediction models for depression in patients with coronary heart disease: a systematic review and meta-analysis
Background: Risk prediction models for depression in patients with coronary heart disease are increasingly being developed. However, the quality and applicability of these models in clinical practice remain uncertain.Objective: To systematically evaluate depression risk prediction models in patients with coronary heart disease (CHD).Methods: Databases including PubMed, Web of Science, Embase, Cochrane Library, CNKI, Wanfang, VIP, and SinoMed were searched for relevant studies from inception to September 29, 2024. Two researchers independently screened the literature, extracted data, and used the Prediction Model Risk of Bias Assessment Tool (PROBAST) to evaluate the models' risk of bias and applicability.Results: Eight studies, encompassing 13 risk prediction models and involving 8,035 CHD patients, were included, with 1,971 patients diagnosed with depression. Common predictors included age, educational level, gender, and cardiac function classification. The area under the curve (AUC) for the models ranged from 0.772 to 0.961, indicating overall good performance; however, risk of bias was high, primarily due to issues in the analysis phase, such as inadequate handling of missing values, univariate analysis for variable selection, and lack of external validation.Conclusion: Depression risk prediction models for CHD patients generally perform well, but high risk of bias and limited applicability remain concerns. Future studies should focus on developing and validating more robust models to aid healthcare professionals in early identification of high-risk patients for depression.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024625641, identifier (CRD42024625641).
- 15 January 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1522619
Open AccessRisk prediction models for depression in patients with coronary heart disease: a systematic review and meta-analysis
Background: Risk prediction models for depression in patients with coronary heart disease are increasingly being developed. However, the quality and applicability of these models in clinical practice remain uncertain.Objective: To systematically evaluate depression risk prediction models in patients with coronary heart disease (CHD).Methods: Databases including PubMed, Web of Science, Embase, Cochrane Library, CNKI, Wanfang, VIP, and SinoMed were searched for relevant studies from inception to September 29, 2024. Two researchers independently screened the literature, extracted data, and used the Prediction Model Risk of Bias Assessment Tool (PROBAST) to evaluate the models' risk of bias and applicability.Results: Eight studies, encompassing 13 risk prediction models and involving 8,035 CHD patients, were included, with 1,971 patients diagnosed with depression. Common predictors included age, educational level, gender, and cardiac function classification. The area under the curve (AUC) for the models ranged from 0.772 to 0.961, indicating overall good performance; however, risk of bias was high, primarily due to issues in the analysis phase, such as inadequate handling of missing values, univariate analysis for variable selection, and lack of external validation.Conclusion: Depression risk prediction models for CHD patients generally perform well, but high risk of bias and limited applicability remain concerns. Future studies should focus on developing and validating more robust models to aid healthcare professionals in early identification of high-risk patients for depression.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024625641, identifier (CRD42024625641).
- Open Access
- 19 May 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Herb-symptom analysis of Erchen decoction combined with Xiebai powder formula and its mechanism in the treatment of chronic obstructive pulmonary disease
Background: In recent years, the incidence and mortality rates of chronic obstructive pulmonary disease (COPD) have increased significantly. Erchen Decoction combined with Xiebai Powder (ECXB) formula is mainly used to treat lung diseases in traditional Chinese medicine (TCM). However, the active ingredients of ECXB formula, COPD treatment-related molecular targets, and the mechanisms are still unclear. To reveal its underlying action of mechanism, network pharmacology, molecular docking, and molecular dynamic (MD) simulation approaches were used to predict the active ingredients and potential targets of ECXB formula in treating COPD. As a result, Herb-Symptom analysis showed that the symptoms treated by both TCM and modern medicine of ECXB formula were similar to the symptoms of COPD. Network pharmacology identified 170 active ingredients with 137 targets, and 7,002 COPD targets was obtained. 120 targets were obtained by intersection mapping, among which the core targets include MAPK8, ESR1, TP53, MAPK3, JUN, RELA, MAPK1, and AKT1. Functional enrichment analysis suggested that ECXB formula might exert its treat COPD pharmacological effects in multiple biological processes, such as cell proliferation, apoptosis, inflammatory response, and synaptic connections, and ECXB formula treated COPD of the KEGG potential pathways might be associated with the TNF signaling pathway, cAMP signaling pathway, and VEGF signaling pathway. Molecular docking showed that ECXB formula treatment COPD core active ingredients can bind well to core targets. MD simulations showed that the RELA-beta-sitosterol complex and ESR1-stigmasterol complex exhibited higher conformational stability and lower interaction energy, further confirming the role of ECXB formula in the treatment of COPD through these core components and core targets. Our study analyzed the medication rule of ECXB formula in the treatment of COPD from a new perspective and found that the symptoms treated by both TCM and modern medicine of ECXB formula were similar to the symptoms of COPD. ECXB formula could treat COPD through multi-component, multi-target, and multi-pathway synergistic effects, providing a scientific basis for further study on the mechanism of ECXB formula treatment of COPD. It also provides new ideas for drug development.
- 19 May 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Open AccessHerb-symptom analysis of Erchen decoction combined with Xiebai powder formula and its mechanism in the treatment of chronic obstructive pulmonary disease
Background: In recent years, the incidence and mortality rates of chronic obstructive pulmonary disease (COPD) have increased significantly. Erchen Decoction combined with Xiebai Powder (ECXB) formula is mainly used to treat lung diseases in traditional Chinese medicine (TCM). However, the active ingredients of ECXB formula, COPD treatment-related molecular targets, and the mechanisms are still unclear. To reveal its underlying action of mechanism, network pharmacology, molecular docking, and molecular dynamic (MD) simulation approaches were used to predict the active ingredients and potential targets of ECXB formula in treating COPD. As a result, Herb-Symptom analysis showed that the symptoms treated by both TCM and modern medicine of ECXB formula were similar to the symptoms of COPD. Network pharmacology identified 170 active ingredients with 137 targets, and 7,002 COPD targets was obtained. 120 targets were obtained by intersection mapping, among which the core targets include MAPK8, ESR1, TP53, MAPK3, JUN, RELA, MAPK1, and AKT1. Functional enrichment analysis suggested that ECXB formula might exert its treat COPD pharmacological effects in multiple biological processes, such as cell proliferation, apoptosis, inflammatory response, and synaptic connections, and ECXB formula treated COPD of the KEGG potential pathways might be associated with the TNF signaling pathway, cAMP signaling pathway, and VEGF signaling pathway. Molecular docking showed that ECXB formula treatment COPD core active ingredients can bind well to core targets. MD simulations showed that the RELA-beta-sitosterol complex and ESR1-stigmasterol complex exhibited higher conformational stability and lower interaction energy, further confirming the role of ECXB formula in the treatment of COPD through these core components and core targets. Our study analyzed the medication rule of ECXB formula in the treatment of COPD from a new perspective and found that the symptoms treated by both TCM and modern medicine of ECXB formula were similar to the symptoms of COPD. ECXB formula could treat COPD through multi-component, multi-target, and multi-pathway synergistic effects, providing a scientific basis for further study on the mechanism of ECXB formula treatment of COPD. It also provides new ideas for drug development.
- Open Access
- 1 August 2020
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 52, 102476
Spraying rhubarb powder solution under gastroscope in the treatment of acute non-varicose upper gastrointestinal bleeding: A systematic review and meta-analysis of randomized controlled trials
- 1 August 2020
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 52, 102476
Open AccessSpraying rhubarb powder solution under gastroscope in the treatment of acute non-varicose upper gastrointestinal bleeding: A systematic review and meta-analysis of randomized controlled trials